Interestingly, the idea of leveraging the effects of a targeted drug regimen by combining it with IFN-γ is an approach that we are already testing in a pilot clinical trial (NCT03112590) in the setting of locally advanced HER-2pos breast cancer. Here, IFNG is linked to breast cancer.